DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
compose your message
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
SPCI Launched the SCOT (Sickle Cell Omega-3 Treatment) Trial in the United States with an Investigator Meeting Held December 16-17 in Atlanta
Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced the start of the first of two placebo controlled clinical trials in US pediatric patients affected with Sickle Cell Disease (SCD). Recruitment in the trial is underway and enrollment is expected to be completed by Q2 2017 and will be immediately followed by a second placebo controlled clinical study in Q3 2017.
SCD is estimated to affect 100,000 Americans, with a disproportional impact on African Americans.
“It has taken us nearly 3 years to get to the point of dosing children in the United States who have this horrible disease. I am excited by the data we’ve seen in studies performed abroad, but having only children from the United States in such a study will be exciting and conclusive,” said Dr. Frederick Sancilio, CEO of SPCI.
education & researchCrizanlizumab for the Prevention of Pain Crises in Sickle Cell DiseaseBACKGROUND: The up-regulation of P-selec...
news & eventsExperimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
news & eventsChief Patient Officer SummitJuly 18-20 | Boston, Massachusetts This...
news & eventsLa Jolla Pharmaceutical company announces initiation of pivotal clinical study of LJPC-401 in patients with beta tha...La Jolla Pharmaceutical company today an...
news & eventsGlobal Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSM...Global Blood Therapeutics, Inc. (GBT) (N...
news & eventsGamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem MeetingsGamida Cell, a leading cellular and immu...
news & eventsNovel Sickle Cell Drug Causes Radical Results in End of Life PatientsThis week the FDA approved a novel treat...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.